STAB — Statera Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $5.97m
- $1.49m
Annual cashflow statement for Statera Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -9.84 | -3.71 | -3.16 | -2.44 | -102 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4.36 | -1.03 | -0.122 | -0.12 | 72.2 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.15 | 0.105 | 0.608 | 0.174 | 0.851 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.61 | -4.61 | -2.66 | -2.37 | -28.2 |
| Capital Expenditures | -0.004 | -0.028 | -0.002 | — | -0.183 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.89 | 3.99 | 0.158 | 0.055 | 13.6 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 3.89 | 3.97 | 0.157 | 0.055 | 13.5 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0 | 0.055 | 0 | 3.17 | 21 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.67 | -0.613 | -2.49 | 0.82 | 6.25 |